MorphoSys (MOR)

Business description

MorphoSys is a German biotechnology company that uses its proprietary antibody platforms to produce human antibodies for therapeutic use across a range of indications for partners and to develop its own pipeline.

Share price chart

Share chart

Stock data

Market cap.€1633.8m
Last close€62.310
High / Low (52 weeks)€71.9 / €30.8
Stock market listingFRA
Forecast net cash (€m)343.1
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual(9.4)(4.1)91.7
Relative *(12)0.058.1

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Achillion Acorda Therapeutics
Active Biotech Addex Therapeutics
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris Agennix
Alchemia Alexza Pharmaceuticals
Algeta ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarin AmpliPhi Biosciences
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Aratana Therapeutics
Ardea Biosciences Arena Pharmaceuticals
Ariad Pharmaceuticals Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Astex Pharmaceuticals
Athersys AVEO Pharmaceuticals
Basilea Bavarian Nordic
Bellus Health Benitec Biopharma
BioAlliance Pharma BioCryst Pharmaceuticals
BioInvent BioLineRx
Bionomics Bionor Pharma
Biota Holdings Biotie Therapies Corp
Biotron BTG
Can-Fite BioPharma Cardio3 BioSciences
Celldex Therapeutics Cellectis
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen
Clinuvel Consort Medical
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Delcath Systems Deltex Medical
Derma Sciences DiaSorin
Diaxonhit e-Therapeutics
EKF Diagnostics Endocyte
Epigenomics Epistem Holdings
Erytech Pharma Esperion Therapeutics
Evolva Evotec
Exact Sciences Exelixis
Formycon Futura Medical
Galapagos Genfit
Genmab GeoVax
GI Dynamics Gilead Sciences
GW Pharmaceuticals Halozyme Therapeutics
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunodiagnostic Systems Holdings ImmuPharma
Imperial Innovations Incyte Corporation
Infinity Pharmaceuticals Innate Pharma
Insmed Invion
Ion Beam Applications Ipsogen
Ironwood Pharmaceuticals Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals LCA-Vision
LeMaitre Vascular Lifeline Scientific
Ligand Pharmaceuticals Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
Medigene Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
MolMed Mologen AG
Nanobiotix Nanosonics
Nektar Therapeutics Neovacs
Newron Pharmaceuticals NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novogen NPS Pharmaceuticals
Omega Diagnostics Group OncoGenex Pharmaceuticals
Oncolytics Biotech Inc OncoMed Pharmaceuticals
Onconova Therapeutics Oncothyreon
Onyx Pharmaceuticals OPMEDIC Group
Optos Orexigen Therapeutics
Orexo OvaScience
Oxford BioMedica Paion
Paladin Labs Patheon
Pharmacyclics Pharmaxis
Pharming Group Photocure
Phylogica Prima BioMed
ProMetic Life Sciences Prosensa
Proteome Sciences QRxPharma
Regeneus Resverlogix
REVA Medical Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes Stem Cell Therapeutics
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis Synergy Health
Synta Pharmaceuticals Tekmira
TESARO Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Topotarget Transgene
Trimel Pharmaceuticals UCB
United Drug Vectura
Verastem Verisante Inc
Vernalis Vertex Pharmaceuticals
Viralytics ViroPharma
Vivalis Vivus
WaferGen Biosystems Wilex
Zealand Pharma Zeltia
Ziopharm Oncology

Company news

MorphoSys AG: Announcement of the Convening of the AGM in Munich ...

Fri, 11 Apr 2014 12:56:15 GMT

MorphoSys to Present at Two Upcoming Investor Conferences

Mon, 31 Mar 2014 09:00:00 GMT

Biametrics Successfully Finalizes Feasibility Study with MorphoSys in the Area ...

Tue, 01 Apr 2014 14:37:30 GMT

(Menafn - GLOBE NEWSWIRE via COMTEX)

Fri, 11 Apr 2014 13:30:00 GMT

Cohen's Point72 Asset Management buys a stake in Cytokinetics

Thu, 17 Apr 2014 17:15:00 GMT

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2012A 51.9 8.8 7.1 27.9 223.3 690.0
2013A 78.0 14.8 10.7 30.1 207.0 16.9
2014E 62.0 (10.3) (8.1) (17.2) N/A N/A
2015E 62.9 (16.5) (14.7) (35.3) N/A N/A

Last updated on 28/03/2014

Investment summary

MorphoSys has a broad portfolio of 20 antibodies in clinical studies (Novartis recently started a pivotal trial with bimagrumab), including three proprietary products with considerable potential. In June, its lead proprietary product, MOR103, was licensed to GSK in a €450m (c $590m) deal for development in all indications globally. A month later, it partnered MOR202 with Celgene in an $818m (c €630m) co-development agreement for multiple myeloma and other haematological cancers. A Phase II study with MOR208 in Non-Hodgkin's lymphoma and acute lymphoblastic leukaemia is ongoing, and another in chronic lymphocytic leukaemia in combination with lenalidomide has also started. MorphoSys had a cash position of €391m on 31 December, which will be used to support the MOR208 programme, other proprietary programmes and potential acquisitions, as well as fulfil its commitments with MOR202's development.

Last updated on 31/03/2014

Industry outlook

The pharmaceutical industry is out-licensing more drug discovery and developing more biological products, both trends that should benefit MorphoSys. Also, there is increasing demand for novel therapies, such as those in MorphoSys' proprietary pipeline.

Last updated on 31/03/2014

Key management

Gerald Moller, Chairman
Simon E. Moroney, CEO
Jens Holstein, CFO

Company address

Lena-Christ-Str. 48
82152 Martinsried/Planegg
Germany
+49 (0)89 / 899 27-0
View website